OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Yadav on the Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma

September 10th 2019

Ghanshyam Yadav, MD, discusses research surrounding the combination of the PARP inhibitor olaparib and the pan-HER TKI neratinib, which proved to be highly synergistic and had significant activity in preclinical models of HER2-positive uterine serous carcinoma.

Dr. Gupta on Enzalutamide/Chemo Combo in Metastatic Bladder Cancer

September 10th 2019

Shilpa Gupta, MD, associate professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the results of the phase I/Ib trial investigating the use of frontline enzalutamide, gemcitabine and cisplatin in metastatic bladder cancer.

Dr. Davis on the ANZUP Collaboration on the ENZAMET Trial in Prostate Cancer

September 10th 2019

Ian Davis, MBBS, PhD, FRACP, FAChPM, professor of medicine at Monash University and Eastern Health, and head of the Eastern Health Clinical School, discusses the Australian and New Zealand Urogenital and Prostate Cancer Trials Group collaboration on the randomizedphase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Marks on PHENIX Trial Data in HER2+ Breast Cancer

September 10th 2019

Douglas K. Marks, MD, discusses data from a small subset of patients with HER2-positive breast cancer enrolled in the PHENIX trial, which was presented at the 2019 ASCO Annual Meeting.

Dr. Ghia on ASCEND Trial Results for Previously Treated CLL

September 10th 2019

Paolo Ghia, MD, discusses the efficacy results of the ASCEND trial, which examined the use of acalabrutinib monotherapy in patients with previously treated chronic lymphocytic leukemia.

Dr. Sonpavde on Immunotherapy After Progression in Advanced Bladder Cancer

September 10th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the use of immunotherapy after progression on platinum-based therapy in advanced bladder cancer.

Dr. Henderson on Anticipated Developments With Radiotherapy in Prostate Cancer

September 10th 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology, associate medical director, University of Florida Health Proton Therapy Institute, discusses anticipated developments with radiotherapy in prostate cancer.

Dr. Polsky on Validating ctDNA as a Biomarker in BRAF-Mutant Melanoma

September 10th 2019

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the next steps that have to be taken to validate the clinical utility of circulating tumor DNA (ctDNA) as a biomarker in BRAF-mutant melanoma.

Dr. Tolba on Targeting NRG1 Fusions in NSCLC

September 10th 2019

Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non-small cell lung cancer.

Dr. Graff Underscores Unmet Needs in ESR1-Mutated Breast Cancer

September 9th 2019

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses some unmet needs of patients with ESR1-mutated metastatic breast cancer.

Dr. Eradat on Novel Therapy Vs Chemotherapy in CLL

September 7th 2019

Herbert A. Eradat, MD, compares novel therapies with cytotoxic chemotherapy in the treatment of patients with chronic lymphocytic leukemia.

Dr. Hershman on the Equivalency of Biosimilars and Biologics

September 6th 2019

Dawn L. Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, leader of the breast cancer program at NewYork-Presbyterian/Columbia University Irving Medical Center, discusses the equivalency of biosimilars and biologics.

Dr. Snyder Discusses Ongoing Research in Myelofibrosis

September 6th 2019

David S. Snyder, MD, associate chair, Department of Hematology and Hematopoietic Cell Transplantation, professor, Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses ongoing research in myelofibrosis.

Dr. Fakih on Future Directions in CRC

September 6th 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses future directions in metastatic colorectal cancer (mCRC).

Dr. Robert on Potential of Dabrafenib/Trametinib in Melanoma Brain Metastases

September 6th 2019

Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussey, co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, explains why patients with melanoma and brain metastases were excluded from a trial evaluating the efficacy of dabrafenib plus trametinib.

Dr. Wang on Combatting CAR T-Cell Therapy Resistance in MCL

September 6th 2019

Michael Wang, MD, discusses resistance to CAR T-cell therapy and the next steps to overcoming this challenge in treatment for mantle cell lymphoma.

Metformin Plus Chemoradiation Induces Antitumorigenic Immune Response in HNSCC

September 6th 2019

Vidhya Karivedu, MD, fellow/resident at the University of Cincinnati College of Medicine, discusses the antitumorigenic immune response seen with the combination of metformin and chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.

Dr. Levis on Gilteritinib in Relapsed/Refractory FLT3-Mutated AML

September 6th 2019

Mark James Levis, MD, PhD, program leader of Hematologic Malignancies and Bone Marrow Transplant Program at Sidney Kimmel Comprehensive Cancer Center, and professor of oncology, Johns Hopkins Medicine, discusses an analysis of gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia harboring other common co-mutations or a high FLT3-internal tandem duplication allelic ratio.

Emerging CAR T-Cell Therapies in Hematologic Cancers

September 6th 2019

Xiuli Wang, PhD, discusses emerging CAR T-cell therapy in hematologic cancers.

Dr. Farago on Frontline Immunotherapy Versus Maintenance Immunotherapy in SCLC

September 6th 2019

Anna F. Farago, MD, PhD, medical oncologist at the Center for Thoracic Cancers at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses the use of frontline immunotherapy versus maintenance immunotherapy in patients with small cell lung cancer (SCLC).